Catalyst Pharmaceuticals Inc

Healthcare · Biotechnology

31.50$ +0.0% vs. previous close Closing price · As of: Jul 21, 2026

Statements

Balance Sheet

Catalyst Pharmaceuticals Inc (CPRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Total Assets" came in at 1,148 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet CPRX
Line item	Q2 16	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Total Assets	49	45	42	38	36	35	85	79	74	68	60	61	78	97	112	118	131	175	192	197	209	223	238	247	267	333	376	407	444	413	470	647	706	772	851	909	972	1,052	1,107	1,148
Current Assets	49	45	41	37	36	34	85	79	69	62	55	55	72	91	111	117	131	143	159	162	176	193	210	221	243	276	321	199	241	192	219	405	474	539	624	686	759	852	894	940
Cash	19	18	14	10.0	8.6	7.3	57	20	9.9	11	17	19	23	45	90	102	115	117	130	127	135	155	171	178	211	256	298	148	179	121	138	310	376	442	518	581	653	690	709	756
Cash & Short-Term Investments	48	45	40	37	35	34	84	78	68	62	53	46	60	77	95	102	115	127	140	143	155	175	191	198	221	256	298	148	179	121	138	310	376	442	518	581	653	690	709	756
Receivables	–	–	–	–	–	–	–	–	–	–	–	7.3	10	10	11	6.9	6.8	5.9	6.0	5.6	6.3	6.6	6.6	11	9.6	9.3	10	33	43	48	54	61	57	58	65	72	66	107	128	131
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.6	2.0	2.2	1.8	4.7	4.7	4.4	7.1	7.0	7.9	7.8	7.9	7.1	6.8	10	11	9.0	16	20	18	20	20	20	19	28	37	35
Property, Plant & Equipment	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.9	4.1	1.0	4.0	0.9	0.9	0.9	0.8	1.3	3.8	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	33	32	184	176	167	194	185	175	166	157	147	138	129	132	122
Total Liabilities	2.6	2.4	2.4	2.6	2.0	2.9	4.4	2.9	3.2	3.6	9.7	9.9	15	19	25	18	20	18	23	19	20	25	31	27	26	63	75	74	69	65	82	85	98	111	124	115	116	131	153	135
Current Liabilities	2.3	2.0	2.1	1.9	1.8	2.7	4.3	2.7	3.1	3.5	9.5	9.0	14	18	24	18	20	18	23	14	16	21	27	23	22	45	58	57	53	58	76	80	92	105	121	112	113	129	147	132
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	–	0.3	0.3	0.3	0.3	0.3	0.2	0.1	0.0	0.1	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.4
Accounts Payable	0.7	1.1	0.9	0.9	0.7	1.1	1.9	0.8	0.9	1.3	2.3	2.9	3.3	4.1	4.1	1.3	5.8	2.0	4.3	2.6	2.9	2.8	2.8	5.1	2.3	2.5	4.0	3.4	4.4	4.6	15	10	7.1	12	17	11	5.5	9.1	11	7.2
Long-Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	0.9	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	46	43	39	35	34	32	81	76	71	64	51	51	63	78	88	100	111	157	170	179	189	199	207	220	241	270	300	334	375	349	388	561	609	661	728	794	856	920	954	1,013
Retained Earnings	-100	-104	-108	-113	-117	-121	-127	-132	-138	-146	-161	-161	-150	-137	-129	-118	-108	-65	-54	-46	-38	-33	-26	-16	1.6	24	50	79	117	86	121	145	185	229	285	342	394	447	474	523
Shares Outstanding	83	83	83	83	84	85	91	103	103	103	103	103	106	107	107	107	107	106	106	107	108	108	109	109	109	112	114	114	114	107	114	123	125	125	126	127	128	127	127	127

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: July 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings